From Traditional Pharmacological Towards Nucleic Acid-based Therapies for Cardiovascular Diseases

Ulf Landmesser; Wolfgang Poller; Sotirios Tsimikas; Patrick Most; Francesco Paneni; Thomas F. Lüscher


Eur Heart J. 2020;41(40):3884-3899. 

In This Article

Note Added in Proof

During proofreading the results of four important clinical trials became published:

  • Ray KK et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020, doi: 10.1056/NEJMoa1912387, ORION-10 and ORION-11 (NCT03399370 and NCT03400800);

  • Raal FJ et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020, doi: 10.1056/NEJMoa1913805, ORION-9 (NCT03397121);

  • Ray KK et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2020, doi: 10.1001/jama.2020.3308, BETonMACE (NCT02586155).